4/A: Centessa CPO Amends Option Exercise, Sells Shares

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, amended a Form 4 filing to correct details of stock option exercises and subsequent share sales under a pre-arranged trading plan.

Summary

• Karen M. Anderson, Centessa Pharmaceuticals' Chief People Officer, filed an amended Form 4 to correct previously reported stock option exercises.
• The amendment clarifies that exercises on March 13, 2026, originated from two separate option grants with different exercise prices, not a single grant.
• Anderson exercised options to acquire 94,224 Ordinary Shares at $4.01 per share and 15,174 Ordinary Shares at $3.85 per share.
• Concurrently, Anderson sold 107,961 Ordinary Shares at a weighted average price of $26.1505 (ranging from $25.75 to $26.705) and 12,068 Ordinary Shares at a weighted average price of $27.1328 (ranging from $26.805 to $27.455).
• These sales were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025.
• Following these transactions, Anderson directly beneficially owns 62,085 Ordinary Shares and 178,147 share options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While insider selling can be a concern, the use of a 10b5-1 plan and the amendment for clarification suggest routine executive compensation management rather than a negative signal.

Positives

• The Chief People Officer exercised options at significantly lower prices ($4.01 and $3.85) compared to the sale prices ($26.1505 and $27.1328), indicating substantial personal profit.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than a reaction to new, undisclosed information.

Negatives

• A key executive sold a significant number of shares (120,029 shares in total), which could be interpreted by some investors as a lack of confidence, although mitigated by the 10b5-1 plan.

Future Outlook

The remaining 75% of one option grant will vest and become exercisable in 36 monthly installments on the first day of each month, following the initial 25% vesting on December 1, 2023. For another option grant, 1/48th of the shares will vest and become exercisable in equal monthly installments, with the first installment vesting on March 1, 2023.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by the market. While sales under a 10b5-1 plan are generally viewed as less concerning than open-market sales, they still represent an executive diversifying their holdings. This amendment provides clearer disclosure regarding the source of the exercised options.

Comparison to Industry Standards

• The exercise of options and subsequent sale at a significant profit margin is a common practice for executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where equity compensation is prevalent.
• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations by pre-scheduling transactions.
• Compared to similar executive compensation events at peer biotech firms, the profit margins realized by Ms. Anderson appear substantial, reflecting a strong appreciation in Centessa's stock price since the option grants.

Stakeholder Impact

• Shareholders: May view the executive's sale of shares with slight caution, though the 10b5-1 plan mitigates concerns. The amendment provides clearer disclosure regarding the transactions.

Next Steps

• Remaining shares subject to one option grant will continue to vest in 36 monthly installments.
• Remaining shares subject to another option grant will continue to vest in equal monthly installments.

Key Dates

Recommendation

This filing is an amendment to correct reporting details of a pre-scheduled insider transaction. While an executive selling shares can sometimes be a negative signal, the use of a 10b5-1 plan indicates a planned liquidity event rather than a reaction to new information. The amendment itself is a technical correction, not indicative of new fundamental information. Therefore, it does not warrant a change in investment thesis, suggesting a 'Hold' recommendation.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4/A, insider trading, stock options, share sale, Rule 10b5-1, executive compensation, Karen M. Anderson